Bal Pharma Intrinsic Value
Bal Pharma (BALPHARMA) median intrinsic value is ₹139.67 from 9 valuation models (range ₹58–₹199), vs current price ₹87.34 — +59.9% upside (Trading Below Calculated Value), margin of safety 37.5%. Read Bal Pharma dividend payments for the complete payout history and dividend yield track record.
BALPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Bal Pharma intrinsic value across 9 models vs current price ₹87.34 — upside/downside and value range per method. For current market price and key ratios, visit Bal Pharma share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹198.88 | ₹159.10 - ₹238.66 | +127.7% | EPS: ₹9.04, Sector P/E: 22x |
| Book Value Method | asset | ₹102.50 | ₹92.25 - ₹112.75 | +17.4% | Book Value/Share: ₹51.25, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹174.68 | ₹157.21 - ₹192.15 | +100.0% | Revenue/Share: ₹210.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹174.68 | ₹157.21 - ₹192.15 | +100.0% | EBITDA: ₹40.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹116.05 | ₹92.84 - ₹139.26 | +32.9% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹57.86 | ₹52.07 - ₹63.65 | -33.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹139.67 | ₹125.70 - ₹153.64 | +59.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹140.00 | ₹126.00 - ₹154.00 | +60.3% | ROE: 19.5%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹102.10 | ₹91.89 - ₹112.31 | +16.9% | EPS: ₹9.04, BVPS: ₹51.25 |
BALPHARMA Intrinsic Value vs Market Price — All Valuation Models
Bal Pharma fair value range ₹58–₹199 vs current market price ₹87.34 across 9 valuation models. Analyse Bal Pharma ownership structure to track promoter, FII and institutional holdings.
BALPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Bal Pharma median intrinsic value ₹139.67, current price ₹87.34 — Trading Below Calculated Value by 59.9%, margin of safety 37.5%.
What is the intrinsic value of BALPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Bal Pharma (BALPHARMA) is ₹139.67 (median value). With the current market price of ₹87.34, this represents a +59.9% variance from our estimated fair value.
The valuation range spans from ₹57.86 to ₹198.88, indicating ₹57.86 - ₹198.88.
Is BALPHARMA undervalued or overvalued?
Based on our multi-method analysis, Bal Pharma (BALPHARMA) appears to be trading below calculated value by approximately 59.9%.
BALPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Bal Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.95 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 19.5% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.89x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BALPHARMA Cash Flow Quality — Operating & Free Cash Flow
Bal Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹20 Cr | ₹13 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹23 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-2 Cr | ₹-13 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹27 Cr | ₹22 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹22 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |